Incannex Healthcare Inc ADR (IXHL) Stock Price, Quote & News

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 61 4 0984 0786

Website: www.incannex.com

Address:

8 Century Circuit, Suite 105 Norwest, Sydney, Australia

malibu_rum67 Jul. 7 at 1:56 AM

$IWM $IXHL $SPY

0 · Reply

Soly96 Jul. 7 at 1:55 AM

$IXHL On 5/14 we had over 1.5 billion shares traded . Can we see it again in July?

0 · Reply

StrawberryRips Jul. 7 at 1:49 AM

$IXHL Phase 2 data any day now in July. Strong positive outlook, previously known to run 100’s of %. OSA is a ~$10 Billion market, IXHL at only ~$20. Watching this week, or the next couple, for a big move to the upside on positive data. .20/.22 nice entry. Holding 77k shares at .199 personally. $SPY $IWM

0 · Reply

D1357912 Jul. 7 at 1:23 AM

$IXHL up over 3% overnight trading

0 · Reply

Soly96 Jul. 7 at 1:22 AM

$IXHL

0 · Reply

krispen Jul. 7 at 1:15 AM

$IXHL Two thoughts: 1) Marijuana has been used for sleep related disorders for years prior to cannabinoid product development by people who have been self-medicating to improve their sleep patterns, so it is a small step to see how a properly synthesized cannabinoid product can alleviate one of the leading sleep deficit causes in apnea. 2) Beyond the fact that July has already been stated the timeframe for next PR on IXHL’s OSA product status, it is logical for the release to try and pre-empt another potential tariff increase and it’s market effects at the end of July in anticipation of August impacts as announced by the WH. This may further prompt a sooner than later announcement to catalyze the market by mid-July imho. Just my $0.02 Very BULLISH for a BLAST-OFF any day now! 🔥🔥🔥🚀🚀🚀

1 · Reply

Olivia_Strickland Jul. 7 at 1:08 AM

$IXHL what happened on 4/29 for the sharp dump then on 5/14 the sharp pump to .70? trying to see if this is something I want to scalp tomorrow.

1 · Reply

WangSLO Jul. 7 at 12:43 AM

$IXHL if this is a.p&d, can we at least send it to 35 before dumping @Santa_Claus_Trades

1 · Reply

findom Jul. 7 at 12:37 AM

$IXHL Let’s keep it real and grounded … If IHL‑42X shows strong Phase 2 efficacy and safety, IXHL’s fair market cap could plausibly reach: 🎯 $500 million to $1.5 billion, 📈 compared to ~$50 million today — a potential 10x+ upside, contingent on continued progress. So, at around $500 million, it would be 10x today’s MC, or $2.00 pps (Low). At $1 Billion, $4.00 pps (Med) and $1.5 Billion, $6.00 pps. (High) The above does not reflect any momentary overreaction to the news and FOMO effect.

1 · Reply

WangSLO Jul. 7 at 12:35 AM

$IXHL i think this is the first time i fully think @Santa_Claus_Trades is actually holding

0 · Reply

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Jun 18, 2025, 7:30 AM EDT - 18 days ago

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Jun 17, 2025, 7:30 AM EDT - 19 days ago

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Jun 12, 2025, 7:30 AM EDT - 24 days ago

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jun 3, 2025, 7:30 AM EDT - 4 weeks ago

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

May 29, 2025, 7:30 AM EDT - 5 weeks ago

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

May 28, 2025, 4:21 PM EDT - 5 weeks ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

May 28, 2025, 7:00 AM EDT - 5 weeks ago

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

May 20, 2025, 7:30 AM EDT - 6 weeks ago

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

May 16, 2025, 9:00 AM EDT - 7 weeks ago

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

May 15, 2025, 8:00 AM EDT - 7 weeks ago

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:14 PM EDT - 7 weeks ago

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

May 14, 2025, 8:00 AM EDT - 7 weeks ago

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Apr 3, 2025, 7:30 AM EDT - 3 months ago

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Mar 7, 2025, 2:10 PM EST - 4 months ago

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Feb 18, 2025, 5:51 PM EST - 4 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Feb 14, 2025, 7:30 AM EST - 5 months ago

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Feb 4, 2025, 9:15 AM EST - 5 months ago

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Jan 23, 2025, 7:30 AM EST - 5 months ago

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Dec 2, 2024, 4:48 PM EST - 7 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Nov 14, 2024, 4:05 PM EST - 8 months ago

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Oct 24, 2024, 7:30 AM EDT - 9 months ago

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Oct 2, 2024, 4:50 PM EDT - 9 months ago

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Sep 30, 2024, 4:01 PM EDT - 9 months ago

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Sep 9, 2024, 8:00 AM EDT - 10 months ago

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

Aug 5, 2024, 7:30 AM EDT - 11 months ago

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

May 30, 2024, 7:30 AM EDT - 1 year ago

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 7, 2024, 7:30 AM EDT - 1 year ago

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

May 1, 2024, 2:33 PM EDT - 1 year ago

Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)

Feb 16, 2024, 7:30 AM EST - 1 year ago

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

Feb 1, 2024, 7:30 AM EST - 1 year ago

Clarion Clinics Open for Psychedelic-Assisted Treatments

Jan 24, 2024, 4:05 PM EST - 1 year ago

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Jan 18, 2024, 8:22 AM EST - 1 year ago

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Jan 17, 2024, 7:30 AM EST - 1 year ago

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Dec 21, 2023, 4:05 PM EST - 1 year ago

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Dec 6, 2023, 7:30 AM EST - 1 year ago

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Nov 29, 2023, 1:40 PM EST - 1 year ago

Incannex Healthcare Announces Completion of its Redomiciliation to the United States

Nov 16, 2023, 8:30 AM EST - 1 year ago

Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC

Sep 8, 2023, 7:30 AM EDT - 1 year ago

Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023

Aug 24, 2023, 7:30 AM EDT - 2 years ago

Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD

Aug 22, 2023, 7:30 AM EDT - 2 years ago

Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening

Jul 28, 2023, 7:30 AM EDT - 2 years ago

Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

Jul 26, 2023, 7:30 AM EDT - 2 years ago

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Jul 21, 2023, 9:09 AM EDT - 2 years ago

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Jul 18, 2023, 7:40 AM EDT - 2 years ago

Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea

Jul 10, 2023, 7:30 AM EDT - 2 years ago

Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq

Jul 6, 2023, 8:42 AM EDT - 2 years ago

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company's Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA')

Jun 23, 2023, 8:00 AM EDT - 2 years ago

Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023

malibu_rum67 Jul. 7 at 1:56 AM

$IWM $IXHL $SPY

0 · Reply

Soly96 Jul. 7 at 1:55 AM

$IXHL On 5/14 we had over 1.5 billion shares traded . Can we see it again in July?

0 · Reply

StrawberryRips Jul. 7 at 1:49 AM

0 · Reply

D1357912 Jul. 7 at 1:23 AM

$IXHL up over 3% overnight trading

0 · Reply

Soly96 Jul. 7 at 1:22 AM

$IXHL

0 · Reply

krispen Jul. 7 at 1:15 AM

1 · Reply

Olivia_Strickland Jul. 7 at 1:08 AM

$IXHL what happened on 4/29 for the sharp dump then on 5/14 the sharp pump to .70? trying to see if this is something I want to scalp tomorrow.

1 · Reply

WangSLO Jul. 7 at 12:43 AM

$IXHL if this is a.p&d, can we at least send it to 35 before dumping @Santa_Claus_Trades

1 · Reply

findom Jul. 7 at 12:37 AM

1 · Reply

WangSLO Jul. 7 at 12:35 AM

$IXHL i think this is the first time i fully think @Santa_Claus_Trades is actually holding

0 · Reply

Xvool Jul. 7 at 12:31 AM

$IXHL Top-line results expected July 2025 as development of first-in-class OSA drug advances ! 🚨 Phase 2 top line results this month ! https://www.globenewswire.com/news-release/2025/06/18/3101356/0/en/Incannex-achieves-key-milestone-with-database-lock-for-RePOSA-Phase-2-trial-of-IHL-42X.html

0 · Reply

malibu_rum67 Jul. 7 at 12:29 AM

$IXHL

0 · Reply

malibu_rum67 Jul. 7 at 12:28 AM

$IXHL … I Am Holding A HIGH VALUE ASSET!!! I Feel Rich 🤑 🤭

0 · Reply

malibu_rum67 Jul. 7 at 12:25 AM

$IXHL …. Super Bullish 🐂 💪💪💪

0 · Reply

LetsGoBflo Jul. 7 at 12:11 AM

$IXHL

0 · Reply

Akicker87 Jul. 7 at 12:06 AM

$IXHL .2170

0 · Reply

JRP07 Jul. 6 at 11:57 PM

$IXHL Futures are up. Tomorrow might be a perfect day to release the News!

0 · Reply

Picaxle10 Jul. 6 at 11:02 PM

$IXHL phase 2 data anyday with phase 3 FDA authorization in place 🚀🚀 Ixhl Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance With the FDA authorization in place, Incannex will initiate Phase 3 immediately following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency and speed. “The progression of RePOSA into Phase 3 represents a major milestone for Incannex and our shareholders,” said Joel Latham, President and CEO of Incannex. “IHL-42X is a high-value asset targeting one of the most prevalent and under-treated conditions globally, OSA. With FDA clearance, a streamlined study design, and the drug product already manufactured, we are uniquely positioned to execute efficiently and deliver meaningful value. IHL-42X has the potential to become the first FDA-approved oral therapy for obstructive sleep apnea, and we believe it could transform the treatment paradigm for millions of patients across the globe.”

0 · Reply

malibu_rum67 Jul. 6 at 10:42 PM

$IXHL

0 · Reply

Manika2002 Jul. 6 at 10:33 PM

$IXHL @Santa_Claus_Trades i think you are really IN 👍

0 · Reply

Santa_Claus_Trades Jul. 6 at 10:14 PM

$IXHL Reasons why we would be a good canidate for a future buyout. Cleaned up Capital Structure: Incannex has actively worked to reduce potential future dilution by canceling Series A Warrants, which can make the company more attractive to potential acquirers who prefer a simpler and cleaner capital structure. Upcoming Catalysts: The impending release of Phase 2 data for IHL-42X, a treatment for obstructive sleep apnea, could be a significant event. Positive results could substantially increase the company's value and attract potential buyers interested in this specific therapeutic area. Focus on a First-in-Class Treatment: IHL-42X is highlighted as a potential first-in-class oral therapy for obstructive sleep apnea, a condition with significant unmet medical needs. This could make it a particularly attractive acquisition target for larger pharmaceutical companies looking to enter or expand in this market.

1 · Reply

Santa_Claus_Trades Jul. 6 at 10:03 PM

$IXHL How high could our baby girl go, just on Phase 2 success alone...JMO Positive Market Response: A successful Phase 2 trial for IHL-42X in treating obstructive sleep apnea (OSA) would likely be met with positive market sentiment, potentially leading to a significant increase in the stock price. Addressing an Unmet Need: IHL-42X is designed as a first-in-class oral treatment for OSA, potentially addressing a large market with limited current options. This could drive substantial value for the company and investors. Analyst Estimates: Some analyst forecasts, like Stonegate Capital Partners, have suggested significant upside potential for IXHL, potentially over 200% premium to the current market price, based on successful clinical progression and market opportunities. Eliminating Dilution: Incannex has taken steps to reduce potential future dilution by canceling warrants, which could increase the value per share if IHL-42X succeeds.

0 · Reply

Market Cap	6.16M
Revenue (ttm)	10,000.00
Net Income (ttm)	-18.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-184,600.00%
Debt to Equity Ratio	3.89

Volume	9,262,100
Avg Vol	73,195,156
Day's Range	N/A - N/A
Shares Out	29.43M
Stochastic %K	36%
Beta	7.47
Analysts	Strong Buy
Price Target	N/A